Skip to content
Home » Johnson & Johnson’s (JNJ) CEO Alex Gorsky on Q2 2014 Results – Earnings Call Transcript

Johnson & Johnson’s (JNJ) CEO Alex Gorsky on Q2 2014 Results – Earnings Call Transcript

Source: Seeking Alpha


Johnson & Johnson (NYSE:JNJ)

Q2 2014 Earnings Conference Call

July 15, 2014 8:30 AM ET


Louise Mehrotra – VP of IR

Alex Gorsky – Chairman of The Board of Directors and CEO

Joaquin Duato – Worldwide Chairman, Pharmaceuticals

Paul Stoffels – CSO, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals

Dominic Caruso – VP, Finance and CFO


Matthew Dodds – Citigroup

Michael Weinstein – JP Morgan

Derrick Sung – Sanford Bernstein

Larry Biegelsen – Wells Fargo

Matt Miksic – Piper Jaffray

Josh Jennings – Cowen & Co.

Rick Wise – Stifel

Glenn Novarro – RBC Capital Markets

Bruce Nudell – Credit Suisse

David Lewis – Morgan Stanley

Kristen Stewart – Deutsche Bank

Jay Olson – Goldman Sachs


Good morning, and welcome to the Johnson & Johnson Second Quarter 2014 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. (Operator Instructions).

I would now like to turn the conference call over to Johnson & Johnson. You may begin.

Louise Mehrotra – VP of IR

Good morning and welcome. I’m Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson and it is my pleasure this morning to review our business results for the second quarter of 2014. Joining me on the call today are Alex Gorsky, Chairman of The Board of Directors and Chief Executive Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; Paul Stoffels, Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals; and Dominic Caruso, Vice President, Finance and Chief Financial Officer. A few logistics before we get into the details.

This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson Web site. I’ll begin by briefly reviewing second quarter results for the corporation and for our three business segments. Following my remarks, Alex will provide some additional commentary on the business and an update on our near term priorities. Next, Joaquin and Paul will provide an update on our pharmaceutical business, and lastly Dominic will review the income statement and provide guidance for 2014.

Pages: First |1 | ... | Next → | Last | View Full Transcript